chr3-37017504-A-G
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000249.4(MLH1):c.791-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★★).
Frequency
Consequence
NM_000249.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:2
This variant is considered pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. This variant is strongly associated with more severe personal and family histories of cancer, typical for individuals with pathogenic variants in this gene [PMID: 27363726]. -
- -
Lynch syndrome Pathogenic:2
The c.791-2A>G variant in MLH1 has been reported in at least 4 individuals with Lynch syndrome-related cancers (Samowitz 2001, Parc 2003, Sjursen 2010, Susswein 2015) and in ClinVar (Variation ID: 90372). It was absent from large population studies. This variant occurs within the canonical splice site (+/- 1,2) and is predicted to cause altered splicing leading to an abnormal or absent protein. Furthermore, this variant was found in probands with MSI-high and MLH1-absent colorectal cancers (Samowitz 2001, Sjursen 2010). Loss of function of the MLH1 gene is an established disease mechanism in autosomal dominant Lynch syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Lynch syndrome. ACMG/AMP criteria applied: PVS1, PM2, PS3_Supporting, PS4_Supporting. -
Interrupts canonical donor splice site -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant causes an A to G nucleotide substitution at the -2 position of intron 9 splice acceptor site of the MLH1 gene. This variant is predicted to impair RNA splicing with a likely consequence of out-of-frame skipping of exon 9. RNA studies have demonstrated that this variant results in abnormal splicing (ClinVar SCV000213526.5). This variant has been reported in individuals affected with Lynch syndrome (PMID: 11606497, 12624141, 20587412, 21642682, 30877237) or Lynch syndrome-associated cancers (PMID: 26681312, 29345684). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MLH1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The c.791-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides before coding exon 10 of the MLH1 gene. This alteration was reported in a 56 year old female diagnosed with colon cancer who had many first degree relatives affected with Lynch syndrome associated cancers; more than half of these family members were diagnosed before the age of 50 (Samowitz et al. Gastroenterology. 2001 Oct;121(4):830-8). This alteration was also reported in a Norwegian family that met Amsterdam criteria and had absent MLH1 and PMS2 staining on immunohistochemistry, as well as in a French family that met Amsterdam criteria (Parc Y et al. J Med Genet. 2003 Mar;40(3):208-13; Sjursen et al. J Med Genet. 2010 Sep;47(9):579-85). RNA studies have demonstrated this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -
not provided Pathogenic:1
Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Reported in individuals with personal and/or family history of Lynch-related cancers with at least one tumor showing loss of MLH1 and PMS2 expression (Samowitz et al., 2001; Parc et al., 2003; Sjursen et al., 2010; Bonadona et al., 2011); This variant is associated with the following publications: (PMID: 15331927, 21642682, 25525159, 26681312, 20587412, 12624141, 28152038, 11606497, 30787465) -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change affects an acceptor splice site in intron 9 of the MLH1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with Lynch syndrome (PMID: 11606497, 12624141, 20587412, 21642682; Invitae). It has also been observed to segregate with disease in related individuals. Invitae’s Lynch syndrome clinical variant model, which takes into account the clinical and family history, age, sex, and reported ancestry of multiple individuals with this MLH1 variant, predicts that it is pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model developed at Invitae that incorporates the clinical features of 1,370,736 individuals referred for testing at Invitae. This variant is also known as IVS9-2A>G. ClinVar contains an entry for this variant (Variation ID: 90372). Studies have shown that disruption of this splice site results in skipping of exon 10, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 22949379; Invitae). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at